Edition:
India

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

175.37USD
1:30am IST
Change (% chg)

$0.54 (+0.31%)
Prev Close
$174.83
Open
$175.42
Day's High
$176.66
Day's Low
$171.83
Volume
1,432,787
Avg. Vol
1,649,166
52-wk High
$201.23
52-wk Low
$152.16

Latest Key Developments (Source: Significant Developments)

Amgen Says In April, Co's Board Increased The Amount Authorized Under Co's Stock Repurchase Program By An Additional $5 Bln - SEC Filing
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Amgen Inc ::AMGEN INC SAYS IN APRIL, CO'S BOARD INCREASED THE AMOUNT AUTHORIZED UNDER CO'S STOCK REPURCHASE PROGRAM BY AN ADDITIONAL $5.0 BILLION - SEC FILING.  Full Article

Amgen Says CEO Robert Bradway's FY 2017 Total Compensation Was $16.9 Mln
Thursday, 12 Apr 2018 

April 11 (Reuters) - Amgen Inc ::AMGEN INC SAYS CEO ROBERT BRADWAY'S FY 2017 TOTAL COMPENSATION WAS $16.9 MLN VS $16.9 MLN IN FY 2016 - SEC FILING.  Full Article

FDA Expands Approval Of Blincyto
Thursday, 29 Mar 2018 

March 29 (Reuters) - The U.S. Food and Drug Administration::FDA EXPANDS APPROVAL OF BLINCYTO FOR TREATMENT OF A TYPE OF LEUKEMIA IN PATIENTS WHO HAVE A CERTAIN RISK FACTOR FOR RELAPSE.SAYS GRANTED APPROVAL OF BLINCYTO TO AMGEN.SAYS BLINCYTO CARRIES A BOXED WARNING.  Full Article

Coherus Biosciences Says U.S. Court Grants Motion To Dismiss Patent Infringement Complaint
Tuesday, 27 Mar 2018 

March 26 (Reuters) - Coherus Biosciences Inc ::COHERUS BIOSCIENCES-U.S. COURT ADOPTED MAGISTRATE JUDGE BURKE'S REPORT & RECOMMENDATION TO GRANT MOTION OF CO TO DISMISS PATENT INFRINGEMENT COMPLAINT.COHERUS BIOSCIENCES SAYS PATENT INFRINGEMENT COMPLAINT AGAINST CO WAS FILED BY AMGEN INC & AMGEN MANUFACTURING LIMITED - SEC FILING.COHERUS BIOSCIENCES - PATENT INFRINGEMENT COMPLAINT WAS DISMISSED ON GROUNDS THAT COMPLAINT FAILED TO STATE CLAIM UPON WHICH RELIEF MAY BE GRANTED.  Full Article

Amgen Reports Aimovig Met All Primary, Secondary Endpoints
Tuesday, 23 Jan 2018 

Jan 22 (Reuters) - Amgen Inc ::AMGEN REPORTS AIMOVIG™ (ERENUMAB) MET ALL PRIMARY AND SECONDARY ENDPOINTS IN UNIQUE PHASE 3B STUDY IN EPISODIC MIGRAINE PATIENTS WHO HAVE FAILED MULTIPLE PRIOR PREVENTIVE TREATMENTS.AMGEN INC - FDA HAS SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF MAY 17, 2018.AMGEN INC - IF APPROVED, NOVARTIS AND AMGEN WILL CO-COMMERCIALIZE AIMOVIG IN U.S..AMGEN INC - SAFETY DATA ARE CONSISTENT WITH PREVIOUS STUDIES OF AIMOVIG TO DATE.AMGEN INC - LIBERTY ALSO MET ALL SECONDARY ENDPOINTS, INCLUDING REDUCTION OF MONTHLY MIGRAINE DAYS, REDUCTION IN DAYS NEEDING ACUTE MEDICATION.  Full Article

European Commission Approves Amgen, Allergan's Mvasi
Friday, 19 Jan 2018 

Jan 18 (Reuters) - Amgen Inc ::EUROPEAN COMMISSION APPROVES AMGEN AND ALLERGAN'S MVASI® (BIOSIMILAR BEVACIZUMAB) FOR THE TREATMENT OF CERTAIN TYPES OF CANCER.AMGEN INC - EUROPEAN COMMISSION HAS GRANTED MARKETING AUTHORIZATION FOR MVASI.  Full Article

Amgen Expects To Launch Migraine Drug This Year
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Amgen Inc ::AMGEN CEO SAYS EXPECTS TO BE ABLE TO LAUNCH AIMOVIG FOR MIGRAINE THIS YEAR.AMGEN SAYS EXPECTS TO LAUNCH HUMIRA BIOSIMILAR OUTSIDE U.S. THIS YEAR.AMGEN CEO SAYS BUSINESS DEVELOPMENT DEALS TO REMAIN PRIORITY IN 2018.AMGEN CEO SAYS COMPANY IN STRONGER STRATEGIC POSITION AFTER TAX REFORM.  Full Article

Biocartis And Amgen Sign New Agreement
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Biocartis Group Nv ::REG-BIOCARTIS GROUP NV: BIOCARTIS AND AMGEN SIGN NEW COMPANION DIAGNOSTIC AGREEMENT FOR NOVEL ONCOLOGY COMPOUND.AGREEMENT AIMED AT DEVELOPMENT OF IDYLLA(TM) CDX BIOMARKER TESTS .FINANCIAL DETAILS ON NEW CDX AGREEMENT WITH AMGEN ARE NOT DISCLOSED..  Full Article

FDA Approves XGEVA (Denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Amgen Inc ::FDA APPROVES XGEVA® (DENOSUMAB) FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA.AMGEN INC - APPROVAL IS BASED ON DATA FROM PIVOTAL PHASE 3 '482 STUDY WHICH ENROLLED 1,718 PATIENTS.  Full Article

Amgen Expects To Incur GAAP Net Tax Expense Of Between $6 Bln And $6.5 Bln
Saturday, 23 Dec 2017 

Dec 22 (Reuters) - Amgen Inc ::AMGEN - EXPECTS TO INCUR GAAP NET TAX EXPENSE OF BETWEEN $6 BILLION AND $6.5 BILLION - SEC FILING.AMGEN - EXPECTS TO HAVE ACCESS TO ITS ACCUMULATED GLOBAL CASH AS WELL AS ACCESS TO ITS FUTURE GLOBAL CASH FLOW.AMGEN - UNDER U.S. TAX REFORM LEGISLATION, THE COMPANY’S FUTURE U.S. INCOME GENERALLY WILL BE TAXED AT THE 21 PERCENT U.S. CORPORATE INCOME TAX RATE.AMGEN - UNDER TAX LEGISLATION,EX-U.S. INCOME, INCLUDING PUERTO RICO,GENERALLY WILL BE TAXED IN U.S. AT 10.5% REDUCED BY APPLICABLE FOREIGN TAX CREDITS.AMGEN - NET TAX EXPENSE CHARGE HAS NO IMPACT ON THE COMPANY’S PREVIOUSLY PROVIDED NON-GAAP GUIDANCE.AMGEN - GOING FORWARD, CO DOES NOT EXPECT AN INCREASE IN ITS NON-GAAP TAX RATES AS A RESULT OF THE U.S. TAX REFORM LEGISLATION.  Full Article

BRIEF-Amgen Says In April, Co's Board Increased The Amount Authorized Under Co's Stock Repurchase Program By An Additional $5 Bln - SEC Filing

* AMGEN INC SAYS IN APRIL, CO'S BOARD INCREASED THE AMOUNT AUTHORIZED UNDER CO'S STOCK REPURCHASE PROGRAM BY AN ADDITIONAL $5.0 BILLION - SEC FILING Source text: (https://bit.ly/2FftYIV) Further company coverage: